Allogene Therapeutics Inc (ALLO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Allogene Therapeutics Inc (ALLO) has a cash flow conversion efficiency ratio of -0.094x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-29.69 Million) by net assets ($315.33 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ALLO defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Allogene Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Allogene Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Allogene Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Allogene Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Zhe Kuang Heavy Industry
SHE:300837
|
0.010x |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
-0.128x |
|
Qijing Machinery
SHG:603677
|
0.056x |
|
Hyundai Motor Securities Co. Ltd.
KO:001500
|
-0.045x |
|
Tianjin Realty Development Group Co Ltd
SHG:600322
|
-0.272x |
|
Ningxia Younglight Chemicals Co Ltd
SHE:000635
|
0.008x |
|
Shenzhen Sunyes Electronic Manufacturing Holding Co Ltd
SHE:002388
|
-0.066x |
|
Smcp SAS
PA:SMCP
|
0.110x |
Annual Cash Flow Conversion Efficiency for Allogene Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of Allogene Therapeutics Inc from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of Allogene Therapeutics Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $422.18 Million | $-200.30 Million | -0.474x | -2.23% |
| 2023-12-31 | $512.23 Million | $-237.73 Million | -0.464x | -40.35% |
| 2022-12-31 | $666.88 Million | $-220.52 Million | -0.331x | -65.54% |
| 2021-12-31 | $925.20 Million | $-184.81 Million | -0.200x | -87.38% |
| 2020-12-31 | $1.08 Billion | $-115.09 Million | -0.107x | +51.18% |
| 2019-12-31 | $629.02 Million | $-137.35 Million | -0.218x | -243.85% |
| 2018-12-31 | $703.16 Million | $-44.65 Million | -0.064x | -100.00% |
| 2017-12-31 | $-2.00K | $-44.65 Million | 22326.500x | -- |
About Allogene Therapeutics Inc
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell a… Read more